Abstract: The present disclosure describes, in part, methods for treating a degenerative and vascular disease of the retina and/or posterior segment of the eye in a subject, the method comprising administering to a subject an effective amount of an antibody or fragment thereof that binds to the same epitope as an antibody comprising a heavy chain variable region and a light chain variable region, wherein: (a) the heavy the heavy chain variable region comprises a sequence having at least 85% sequence identity to SEQ ID NO: 4 and the light chain variable region comprises a sequence having at least 85% sequence identity to SEQ ID NO: 5 wherein the antibody inhibits TREM2 cleavage; or (b) the heavy the heavy chain variable region comprises a sequence having at least 85% sequence identity to SEQ ID NO: 6 and the light chain variable region comprises a sequence having at least 85% sequence identity to SEQ ID NO:7, and wherein the antibody inhibits TREM2 cleavage; or (c) the heavy the heavy chain variable region comprises a s

Abstract: This application discloses ophthalmic formulations and methods for treating inflammatory disease and conditions of the ocular surface with one or more C-C chemokine receptor type 7 (CCR7) antagonists. The compositions may be formulated for subconjunctival or topical administration to the eye and are effective in the treatment of inflammatory disease and conditions of the ocular surface.

Abstract: This application discloses ophthalmic formulations and methods for treating inflammatory disease and conditions of the ocular surface with one or more C—C chemokine receptor type 7 (CCR7) antagonists. The compositions may be formulated for subconjunctival or topical administration to the eye and are effective in the treatment of inflammatory disease and conditions of the ocular surface.

Abstract: This application discloses ophthalmic formulations and methods for treating dry eye disease with a C-C chemokine receptor type 7 (CCR7) inhibitor.

Abstract: This application discloses ophthalmic formulations and methods for treating inflammatory disease and conditions of the ocular surface with one or more C-C chemokine receptor type 7 (CCR7) antagonists. The compositions may be formulated for subconjunctival or topical administration to the eye and are effective in the treatment of inflammatory disease and conditions of the ocular surface.

Abstract: A motor driven assembly includes a motor having a motor shaft mounted for rotation about a rotational axis and a rotor radially located about the shaft. The motor drives a compressor that receives air from the motor, compresses the air, and circulates the compressed air to a space. The motor includes a first cooling flow passage and a second cooling flow passage that each receive air to provide internal cooling of the motor. A portion of the air compressed in the compressor is diverted from the compressor to a heat exchanger. The heat exchanger cools the compressed air from before the air circulates into the first cooling flow passage to cool the motor. The second cooling flow passage receives air from the environment surrounding the motor driven assembly to further cool the motor.